Form 4: AbbVie Executive Nicholas Donoghoe Acquires Shares and Options Through Performance Awards

EVP, Chief Business and Strategy Officer of AbbVie, Nicholas Donoghoe, reports acquisition of shares and options related to performance-based awards.

Summary

• Nicholas Donoghoe, EVP, Chief Business and Strategy Officer of AbbVie, filed a Form 4 detailing changes in beneficial ownership.
• On February 13, 2025, Donoghoe acquired 11,017 shares of AbbVie common stock related to a performance share award granted on February 17, 2022.
• He also acquired 4,520 shares related to a performance-vesting restricted stock unit award granted on February 17, 2022.
• Additionally, he acquired 4,634 shares related to a performance-vesting restricted stock unit award granted on February 16, 2023, and 5,174 shares related to a similar award granted on February 15, 2024.
• These shares are subject to performance-vesting restrictions based on earnings per share and relative total shareholder return or relative return on equity measures.
• The performance-vesting restrictions were released upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors.
• The shares will be issued to Donoghoe on February 28, 2025.
• Donoghoe also acquired 23,437 options (right to buy) AbbVie common stock at an exercise price of $192.86 on February 13, 2025, exercisable in installments starting February 13, 2026, and expiring on February 12, 2035.
• Following these transactions, Donoghoe beneficially owns 81,248 shares of common stock and 23,437 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of performance-based awards suggests the company is meeting its goals, which is a positive sign. However, it's a routine disclosure and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The vesting of performance-based awards suggests that AbbVie has met certain performance goals set by the Compensation Committee.
• The acquisition of shares and options by an executive could be interpreted as a sign of confidence in the company's future performance.

Future Outlook

The executive will receive shares on February 28, 2025, and the options become exercisable in annual increments starting February 13, 2026.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies and their executives, providing transparency into insider transactions. This filing indicates that AbbVie's performance has met certain targets, triggering the vesting of performance-based compensation.

Comparison to Industry Standards

• Performance-based compensation is a common practice among large pharmaceutical companies like AbbVie to align executive incentives with shareholder value.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar performance metrics such as earnings per share, relative total shareholder return, and return on equity in their executive compensation plans.
• The vesting schedules and performance targets are typically benchmarked against industry peers to ensure competitiveness and effectiveness.

Stakeholder Impact

• Shareholders may view the vesting of performance-based awards positively, as it suggests the company is achieving its performance targets.
• Employees may be motivated by the fact that executive compensation is tied to company performance.

Next Steps

• The shares will be issued to the reporting person on February 28, 2025.
• The options become exercisable in annual increments starting February 13, 2026.

Key Dates